Skip to main content
SpringerLink
Log in

Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature

  • Original Articles
  • Esorubicin-induced Cardiomyopathy
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A case of fatal dilated cardiomyopathy induced by esorubicin (ESO) at a total dose of 740 mg/m2, given in 27 doses over 650 days, is reported. The sudden onset, rapid clinical deterioration, and fatal outcome are detailed. The outcome was not predicted by serial rest ejection fractions or clinical signs. The data from animal studies, phase 1 and phase 2 clinical testing, are reviewed, demonstrating the almost complete absence of reports of ESO-induced cardiotoxicity. Studies reviewing ejection fractions and myocardial biopsy scores show that ESO can be cardiotoxic and may produce fatal dilated cardiomyopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Armand JP, Hurteloup P, Fargeot P, Kerbrat P, Renard J, Hayat M, Chauvergne J (1985) Phase II trial of esorubicin (4′-deoxydoxorubicin) in advanced colo-rectal cancer (Abstract). Proceedings of the 3rd European Conference on Clinical Oncology and Cancer Nursing, p 112

  2. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62:865–872

    Google Scholar 

  3. Blayney D (1986) Cardiotoxicity associated with 4′-deoxydoxorubicin (Letter). Cancer Treat Rep 70:433

    Google Scholar 

  4. Blayney DW, Leong LA, Goldberg DA, Margolin KA, Carr BI, Akman SA, Doroshow JH (1986) Phase II trial of 4′-deoxydoxorubicin (DXDX) in advanced gastric (GCA) and pancreatic (PCA) cancer (Abstract). Proc Am Assoc Cancer Res 27:179

    Google Scholar 

  5. Bonfante V, Rossi A, Brambilla C, Ferrari L, Fillani F, Comazzi R, Crippa F, Monfardini S, Bonadonna G (1985) Comparative activity and toxicity of adriamycin (ADM) and new anthracycline analogs in advanced breast cancer (Abstract). Proc Am Assoc Cancer Res 26:165

    Google Scholar 

  6. Braich T, Ahmann FR, Garewal HS, Robertone A, Salmon SE (1986) Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer. Invest New Drugs 4: 193–196

    Google Scholar 

  7. Carlson RW, Williams RD, Billingham ME, Pavlos CL, Hannigan JF, Kohler M, Torti FM (1986a) Assessment of the cardiac toxicity of 4′-deoxydoxorubicin (DXDX) utilizing the endomyocardial biopsy score: the NCOG experience (Abstract). Proc Am Soc Clin Oncol 5:52

    Google Scholar 

  8. Carlson RW, Johnson FD, Torti FM, Pavlos CL, Kohler M, Doroshow JH, Billingham ME (1986b) A Phase II trial of 4′-deoxydoxorubicin (DXDX) in the treatment of metastatic carcinoma of the breast: a trial of the Northern California Oncology Group (Abstract). Proc Am Soc Clin Oncol 5:73

    Google Scholar 

  9. Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63:835–844

    Google Scholar 

  10. Casazza AM, DiMarco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerine L (1980) Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD (eds) Anthracyclines: Current status and new developments. Academic Press, New York

    Google Scholar 

  11. Casazza AM, Savi G, Pratesi G, De Marco A (1983) Antitumor activity in mice of 4′-deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clin Oncol 19: 411–418

    Google Scholar 

  12. Ciuliani FC, Kaplan NO (1980) New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40: 4682–4687

    Google Scholar 

  13. Falkson G, Vorobiof DA (1986) Phase II study of 4′-deoxydoxorubicin in advanced colorectal cancer. Invest New Drugs 4: 165–169

    Google Scholar 

  14. Ferrari L, Rossi A, Brambilla C, Bonfante V, Villani F, Crippa F, Bonadonna G (1984) Phase I study with 4′deoxydoxorubicin. Invest New Drugs 2: 287–295

    Google Scholar 

  15. Fiore J, Kemeny N, Raymond V, Young C (1986) Phase II trial of esorubicin in patients with advanced colorectal carcinoma. Cancer Treat Rep 70: 1241–1242

    Google Scholar 

  16. Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R (1984) Phase I trial of esorubicin (4′-deoxydoxorubicin). J Clin Oncol 2: 1034–1039

    Google Scholar 

  17. Hurteloup P, Fumoleau P, Bastit P, Metz R, Renard J, Cauchie C, Armand JP (1985) Phase II trial of esorubicin (4′-deoxydoxorubicin) in advanced renal carcinoma (Abstract). Proc of the 3rd European Conference on Clinical Oncology and Cancer Nursing, p 179

  18. Kish J, Ensley J, Tapazoglou E, Al-Sarraf M (1986) Phase II evaluation of deoxydoxorubicin for patients with advanced and recurrent renal cell cancer (Abstract). Proc Am Soc Clin Oncol 5: 106

    Google Scholar 

  19. LeFrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinico-pathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302–314

    Google Scholar 

  20. Leitner SP, Casper ES, Hakes TB, Kaufman RJ, Winn RJ, Scoppetuolo M, Raymond V, Geller NL, Young CW (1985) Phase II trial of 4′-deoxydoxorubicin in patients with advanced breast cancer. Cancer Treat Rep 69: 1319–1320

    Google Scholar 

  21. Locker G, Hoeltgen R, Kilton, L, Krauss S, Khandekar J, Terebelo H, Johnson C, Blough R (1986) 4′-deoxydoxorubicin (DXDX) in advanced adenocarcinoma of the colon and rectum: An Illinois Cancer Council phase II study (Abstract). Proc Am Soc Clin Oncol 5: 88

    Google Scholar 

  22. Pratesi G, Deschner EE (1984) The antitumoral activity of 4′-deoxydoxorubicin compared to doxorubicin and 5-fluorouracil on methylazoxymethanol acetate-induced colon tumors in CF1 mice. Cancer 54: 18–24

    Google Scholar 

  23. Raymond V, Magill GB, Wissel PS, Cheng EW, Ochoa M, Young CW (1986) Phase II trial of deoxydoxorubicin (DXDX) in patients (PTS) with soft tissue sarcoma (STS) (Abstract). Proc Am Soc Clin Oncol 5: 146

    Google Scholar 

  24. Ringenberg S, Propert K, Perry M, Zimmer B, Weiss R, Richards F, Grazino S, Green M (1986) Deoxydoxorubicin (DXDX) in extensive non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Oncol 5: 174

    Google Scholar 

  25. Ringenberg S, Propert K, Perry M, Weiss RB, Modeas C, Richards F, Graziano S, Hirsh V, Green M (1987) Clinical cardiotoxicity of esorubicin: a prospective study with serial gaited heart scans and report of selected cases (Abstract). Proc Am Soc Clin Oncol 6: 22

    Google Scholar 

  26. Rozencweig M, Crespeigne N, Kenis Y (1983) Phase I trial with 4′ deoxydoxorubicin (esorubicin). Invest New Drugs 1: 309–313

    Google Scholar 

  27. Sessa C, Bosia L, Kaplan S (1984) Phase I trial of 4′deoxydoxorubicin given weekly. Invest New Drugs 2: 369–374

    Google Scholar 

  28. Stanton GF, Raymond V, Wittes RE, Schulmann P, Budman D, Baratz R, Williams L, Petroni Gr, Geller NL, Hancock C, Dreis W, Young CW (1985) Phase I and clinical pharmacological evaluation of 4′deoxydoxorubicin in patients with advanced cancer. Cancer Res 45: 1862–1868

    Google Scholar 

  29. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B (1986) Anthracycline analogs: the past, present and future. Cancer Chemother Pharmacol 18: 185–197

    Google Scholar 

  30. Williams RD, Torti FM, Carlson RW, Hannigan J, Pavlos CL, Billingham ME (1986) A phase II trial of 4′-deoxydoxorubicin (DXDX) in metastatic carcinoma of the kidney: a trial of the Northern California Oncology Group (Abstract). Proc Am Soc Clin Oncol 5: 109

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Walter Reed Army Medical Center, Washington, D. C., USA

    Louis F. Diehl, Alan Banks, Wendy Carter, Michael A. Klein & Raymond B. Weiss

  2. Department of Pathology, Walter Reed Army Medical Center, Washington, D. C., USA

    Louis F. Diehl, Alan Banks, Wendy Carter, Michael A. Klein & Raymond B. Weiss

  3. Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

    Louis F. Diehl, Michael A. Klein & Raymond B. Weiss

  4. Department of Medicine, Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA

    Hyman B. Muss

Authors
  1. Louis F. Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Banks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael A. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyman B. Muss
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raymond B. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The opinions or assertions herein are the private views of the authors and are not to be construed as official or as representing the Department of the Army or the Department of Defense

Supported in part by Grants CA 26806 and CA 03927 from the Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diehl, L.F., Banks, A., Carter, W. et al. Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. Cancer Chemother. Pharmacol. 21, 347–350 (1988). https://doi.org/10.1007/BF00264203

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00264203

Keywords

Search

Navigation